1. Aderinto N, Olatunji G, Kokori E, Sikirullahi S, Aboje JE, et al. A perspective on Oxford,s R21/Matrix-M
™ malaria vaccine and the future of global eradication efforts. Malar J 2024;23(1):16
https://doi.org/10.1186/s12936-024-04846-w
2. World Health Organization. World Malaria Report 2021. Geneva, Switzerland. World Health Organization. Geneva, Switzerland. 2021.
3. Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated
Plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS One 2022;17(3):e0264339
https://doi.org/10.1371/journal.pone.0264339
5. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med 2021;385:1163-1171
https://doi.org/10.1056/NEJMoa2101746
6. Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, et al. Independent emergence of the
Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis 2016;213(9):1472-1475
https://doi.org/10.1093/infdis/jiv752
9. Schmit N, Topazian HM, Natama HM, Bellamy D, Traoré O, et al. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis 2024;24(5):465-475
https://doi.org/10.1016/s1473-3099(23)00816-2
12. Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 2024;403:533-544
https://doi.org/10.1016/s0140-6736(23)02511-4
13. Schneider CG, Fey J, Zou X, Gerbasi V, Savransky T, et al. Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection. Vaccine 2022;40(31):4270-4280
https://doi.org/10.1016/j.vaccine.2022.05.076
14. Yao G, Min H, Yu X, Liu F, Cui L, et al. A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against
Plasmodium berghei. Parasit Vectors 2023;16(1):403
https://doi.org/10.1186/s13071-023-06020-8
15. Tottey S, Shoji Y, Mark Jones R, Musiychuk K, Chichester JA, et al. Engineering of a plant-produced virus-like particle to improve the display of the
Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate. Vaccine 2023;41(4):938-944
https://doi.org/10.1016/j.vaccine.2022.12.048
16. Saveria T, Parthiban C, Seilie AM, Brady C, Martinez A, et al. Needle-free, spirulina-produced
Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice. NPJ Vaccines 2022;7(1):113
https://doi.org/10.1038/s41541-022-00534-5
17. Lee SH, Chu KB, Kang HJ, Basak S, Kim MJ, et al. Virus-like particles expressing
Plasmodium berghei MSP-8 induce protection against
P. berghei infection. Parasite Immunol 2020;42(11):e12781
https://doi.org/10.1111/pim.12781
18. Harmsen C, Turner L, Thrane S, Sander AF, Theander TG, et al. Immunization with virus-like particles conjugated to CIDRα1 domain of
Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies. Malar J 2020;19(1):132
https://doi.org/10.1186/s12936-020-03201-z
19. Kim MJ, Chu KB, Kang HJ, Yoon KW, Lee DH, et al. Influenza virus-like particle vaccine containing both apical membrane antigen 1 and microneme-associated antigen proteins of
Plasmodium berghei confers protection in mice. BMC Immunol 2022;23(1):21
https://doi.org/10.1186/s12865-022-00494-4
20. Lee DH, Chu KB, Kang HJ, Lee SH, Chopra M, et al. Protection induced by malaria virus-like particles containing codon-optimized AMA-1 of
Plasmodium berghei. Malar J 2019;18(1):394
https://doi.org/10.1186/s12936-019-3017-2
21. Chu KB, Kim SS, Lee SH, Lee DH, Kim AR, et al. Immune correlates of resistance to
Trichinella spiralis reinfection in mice. Parasites Hosts Dis 2016;54(5):637-643
https://doi.org/10.3347/kjp.2016.54.5.637
22. Lee SH, Kang HJ, Chu KB, Basak S, Lee DH, et al. Protective immunity induced by virus-like particle containing merozoite surface protein 9 of
Plasmodium berghei. Vaccines (Basel) 2020;8(3):428
https://doi.org/10.3390/vaccines8030428
24. Lal K, Prieto JH, Bromley E, Sanderson SJ, et al. Characterisation of
Plasmodium invasive organelles; an ookinete microneme proteome. Proteomics 2009;9(5):1142-1151
https://doi.org/10.1002/pmic.200800404
25. Dutta S, Haynes JD, Barbosa A, Ware LA, Snavely JD, et al. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of
Plasmodium falciparum. Infect Immun 2005;73(4):2116-2122
https://doi.org/10.1128/iai.73.4.2116-2122.2005
26. Yoshida S, Nagumo H, Yokomine T, Araki H, Suzuki A, et al.
Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines. PLoS One 2010;5(10):e13727
https://doi.org/10.1371/journal.pone.001372
27. Kim MJ, Chu KB, Lee SH, Kang HJ, Yoon KW, et al. Recombinant vaccinia virus expressing
Plasmodium berghei apical membrane antigen 1 or microneme protein enhances protection against
P. berghei infection in mice. Trop Med Infect Dis 2022;7(11):350
https://doi.org/10.3390/tropicalmed7110350
28. Freitas do Rosário AP, Muxel SM, Rodríguez-Málaga SM, Sardinha LR, Zago CA, et al. Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to
Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. J Immunol 2008;181(12):8344-8355
https://doi.org/10.4049/jimmunol.181.12.8344
29. da Silva HB, de Salles EM, Panatieri RH, Boscardin SB, Rodríguez-Málaga SM, et al. IFN-γ-induced priming maintains long-term strain-transcending immunity against blood-stage
Plasmodium chabaudi malaria. J Immunol 2013;191(10):5160-5169
https://doi.org/10.4049/jimmunol.1300462
30. Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, et al. Clusters of cytokines determine malaria severity in
Plasmodium falciparum-infected patients from endemic areas of Central India. J Infect Dis 2006;194(2):198-207
https://doi.org/10.1086/504720
31. Niikura M, Kamiya S, Nakane A, Kita K, Kobayashi F. IL-10 plays a crucial role for the protection of experimental cerebral malaria by co-infection with non-lethal malaria parasites. Int J Parasitol 2010;40(1):101-108
https://doi.org/10.1016/j.ijpara.2009.08.009
33. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe
Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72(10):5630-5637
https://doi.org/10.1128/iai.72.10.5630-5637.2004
35. Weidanz WP, Batchelder JM, Flaherty P, LaFleur G, Wong C, et al.
Plasmodium chabaudi adami: use of the B-cell-deficient mouse to define possible mechanisms modulating parasitemia of chronic malaria. Exp Parasitol 2005;111(2):97-104
https://doi.org/10.1016/j.exppara.2005.06.006
37. Ding Y, Xu W, Zhou T, Liu T, Zheng H, et al. Establishment of a murine model of cerebral malaria in KunMing mice infected with
Plasmodium berghei ANKA. Parasitology 2016;143(12):1672-1680
https://doi.org/10.1017/s0031182016001475
38. Zafar I, Taniguchi T, Baghdadi HB, Kondoh D, Rizk MA, et al.
Babesia microti alleviates disease manifestations caused by
Plasmodium berghei ANKA in murine co-infection model of complicated malaria. Front Cell Infect Microbiol 2023;13:1226088
https://doi.org/10.3389/fcimb.2023.1226088
39. Fitri LE, Sardjono TW, Winaris N, Pawestri AR, Endharti AT, et al.
Bifidobacterium longum administration diminishes parasitemia and inflammation during
Plasmodium berghei infection in mice. J Inflamm Res 2023;16:1393-1404
https://doi.org/10.2147/jir.S400782